Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: Results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques

Purpose: Ten years after the first clinical studies, the clinical impact of myeloid growth factors in acute myeloid leukemia is still unclear. One of the objectives of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques (GO ELAM) 2 trial was to evaluate the benefit of granulocyte colony-stimulating factor (GCSF) given only after the two courses of intensive consolidation chemotherapy (ICC) used to maintain complete remission (CR). Patients and Methods: One hundred ninety-four patients who were in CR after induction treatment were randomly assigned to receive G-CSF (100 patients) or no G-CSF (94 patients) after two courses of ICC (ICC 1, high-dose cytar abine plus mitoxantrone; ICC 2, amsacrine plus etoposide). G-CSF (filgrasti m) was administered from the day after chemotherapy until granulocyte recov ery at a daily dose of 5 mu g/kg. Results: In the G-CSF group, the median duration of neutropenia (< 0.5 x 10 (9)/L) was dramatically reduced, both after ICC 1 (12 v 19 days, P < .001) and after ICC 2 (20 v 28 days, P < .001). The median duration of hospitaliz ation was also significantly shorter in the G-CSF group (24 v 27 days after ICC 1, P < .001; 29 v 34 days after ICC 2, P < .001). The median duration of intravenous antibiotics was significantly reduced after ICC 1 and ICC 2, and the median duration of antifungal therapy was significantly reduced af ter ICC 1. However, the incidence of microbiologically documented infection s, the toxic death rate, the 2-year disease-free survival, and the 2-year o verall survival were not affected by G-CSF administration. Moreover, the me dian interval between ICC 1 and ICC2 was reduced by only 2 days, and the nu mber of patients undergoing ICC2 was not increased in the G-CSF arm. Conclusion: G-CSF should be administered routinely after ICC to reduce the duration of neutropenia and hospitalization. However, G-CSF did not seem to significantly increase the feasibility of this two-course program or modif y overall outcome. (C) 2000 by American Society of Clinical Oncology.